Human Polyclonal CARD8 Ab
- Known as:
- Human Polyclonal CARD8 Antibody
- Catalog number:
- a0293
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- ABclonal
- Gene target:
- Human Polyclonal CARD8
Related genes to: Human Polyclonal CARD8 Ab
- Gene:
- CARD8 NIH gene
- Name:
- caspase recruitment domain family member 8
- Previous symbol:
- -
- Synonyms:
- TUCAN, KIAA0955, CARDINAL, NDPP, Dakar
- Chromosome:
- 19q13.33
- Locus Type:
- gene with protein product
- Date approved:
- 2003-12-03
- Date modifiied:
- 2016-04-25
Related products to: Human Polyclonal CARD8 Ab
Related articles to: Human Polyclonal CARD8 Ab
- Coronary artery calcification (CAC) serves as a significant predictor of cardiovascular events; however, its underlying molecular mechanisms remain incompletely elucidated. PTBP1, an RNA-binding protein with profound regulatory functions, plays a critical role in post-transcriptional regulation. Nevertheless, its function and mechanism in vascular calcification have yet to be fully explored. - Source: PubMed
Publication date: 2026/05/27
Hu HaoZhang FanWu JunMa Likun - - Source: PubMed
Pai Yu-HsuanLin Kan-HsuanYang Shun-ChengHsu Chien-ShengKao Jun-Kai - Lung cancer is the leading cause of cancer-related mortality worldwide, emphasizing the need for innovative therapeutic strategies. This study utilized immunoinformatics and structural bioinformatics approaches to design and evaluate a multi-epitope vaccine targeting pyroptosis-associated antigens (CARD8, NAIP, NLRP1, and NLRP3), which are implicated in lung cancer immunology. Fifteen T-cell and B-cell epitopes were identified, analyzed for their antigenicity, non-toxicity, non-allergenicity, and immune-stimulatory potential, and optimized to construct a vaccine with suitable adjuvants and linkers. The vaccine demonstrated high antigenicity, solubility, and stability, as validated through physicochemical analyses. Its three-dimensional structure was modeled, refined, and validated using molecular modeling approaches. Molecular docking studies revealed stable and strong interactions between the vaccine and key immune receptors (TLR2, TLR4, TLR5, TLR3, TLR7, and TLR8), indicating its potential to activate both innate and adaptive immunity. Molecular dynamics simulations confirmed the vaccine's structural stability and solvent accessibility over 100 ns across ten replicas. Immune simulations demonstrated strong immunogenic responses, including elevated antibody titers, memory cell populations, and cytokine production. Codon optimization and in silico cloning further ensured efficient expression in Escherichia coli, facilitating experimental application. These findings underscore the vaccine's promise as a therapeutic candidate against lung cancer, warranting further in vitro and in vivo investigations. - Source: PubMed
Publication date: 2026/03/19
Nguyen Truc LyKim Heebal - - Source: PubMed
Publication date: 2026/03/04
Du YunZhao BingyeLian Jun - Atherosclerosis, a lipid-driven chronic inflammatory disease, is the primary pathological basis of cardiovascular diseases, characterized by endothelial injury, lipid deposition, immune cell infiltration, and chronic inflammation. The NOD-like Receptor Pyrin Domain-Containing 3 () inflammasome has emerged as a crucial mediator of inflammation in atherosclerosis, with caspase recruitment domain family member 8 (CARD8) acting as a key regulatory component. Indeed, CARD8, a member of the caspase recruitment domain family, regulates immune responses by modulating inflammasome activity, particularly NLRP3. Recent studies suggest that CARD8 influences various aspects of atherosclerotic development, including lipid accumulation, oxidative stress, vascular inflammation, smooth muscle cell proliferation, and plaque instability. Thus, this review summarizes the latest findings on the role of CARD8 in the pathogenesis of atherosclerosis, with a focus on the regulatory effects of this component on immune cells and inflammatory pathways. We also discuss the potential of targeting CARD8 as a therapeutic strategy for atherosclerosis, exploring the current preclinical and clinical evidence. - Source: PubMed
Publication date: 2026/01/21
Tian DandanLiu LiZeng Guang-GuiHe JinrongLiu HuiqinMa DandanYang ZixinMa XiangyanCao YunxiangXu Chunyan